Members |
targetComponentId |
Burn - unspecified |
Burn |
Burn involving 10-14 percent of body surface, with 10-14 percent of body surface with full thickness burn |
Burn involving 10-19 percent of body surface, with 10-14 percent of body surface with full thickness burn (disorder) |
Burn involving 15-19 percent of body surface, with 10-19 percent of body surface with full thickness burn |
Burn involving 10-19 percent of body surface, with 15-19 percent of body surface with full thickness burn (disorder) |
Burn of cornea NOS |
Corneal burn |
Burn of cornea NOS |
Corneal burn |
Burn of eyelid NOS |
Eyelid burn |
Burn of eyelid NOS |
Eyelid burn |
Burn of internal organ NOS |
Burn of internal organ |
Burn of internal organ NOS |
Burn of internal organ |
Burn of other internal organ, NEC |
Burn of internal organ |
Burn of the trunk NOS |
Burn of trunk |
Burn of the trunk NOS |
Burn of trunk |
Burn to arm NOS |
Burn of upper limb |
Burn to arm NOS |
Burn of upper limb |
Burn to cornea - erythema |
Corneal burn |
Burn to cornea - erythema |
Corneal burn |
Burn to head NOS |
Head burn (disorder) |
Burn to head NOS |
Head burn (disorder) |
Bursitis NOS |
Bursitis |
Bursitis NOS |
Bursitis |
Buserelin 150micrograms spray |
Buserelin only product |
Buspirone hydrochloride 5mg tablet |
Buspirone hydrochloride 5 mg oral tablet |
Buspirone hydrochlorine |
Buspirone hydrochloride (substance) |
Butabarbital sodium 30mg/5mL elixir |
Product containing precisely secbutabarbital sodium 6 milligram/1 milliliter conventional release oral solution (clinical drug) |
Butorphanol tartrate 1mg/mL injection solution ampule |
Butorphanol tartrate 1 mg/mL solution for injection |
Butorphanol tartrate 2mg/mL injection solution ampule |
Butorphanol only product in parenteral dose form |
Buttock random pattern flap |
Random pattern flap |
Butyl nitrate - non-pharmaceutical |
Butyl nitrate |
Butyrophenone derivative antipsychotic agent |
Butyrophenone derivative |
Butyrophenone poisoning NOS |
Poisoning by butyrophenone-based tranquilizer |
Bypass complications |
Complication of bypass graft |
Bypass graft mechanical complications |
Complication of bypass graft |
Bypass graft mechanical complications |
Complication of bypass graft |
Bypass of organ NOC |
Construction of shunt |
Byrd respirator therapy |
Respiratory therapy |
C/O - specified symptom findings |
Finding reported by subject or history provider (finding) |
C1 esterase inhibitor 500 units powder for injection solution 8mL vial |
Product containing precisely human C1 esterase inhibitor 500 unit/1 vial powder for conventional release solution for injection (clinical drug) |
CDC Corynebacterium group G-1 |
Corynebacterium accolens |
CDC group DF-2 |
Capnocytophaga canimorsus |
CDE genotype |
CDE haplotype (finding) |
CDe genotype |
CDe haplotype (finding) |
CNS disorders NOS |
Disorder of the central nervous system (disorder) |
CTV3 ROOT |
SNOMED CT Concept |
Ca bone/joint cartilage NOS |
Malignant neoplasm of skeletal system (disorder) |
Ca bone/joint cartilage NOS |
Malignant neoplasm of skeletal system (disorder) |
Ca breast - NOS |
Malignant tumor of breast |
Ca breast - NOS |
Malignant tumor of breast |
Ca cervix uteri NOS |
Malignant tumour of cervix |
Ca cervix uteri NOS |
Malignant tumour of cervix |
Ca colon NOS |
Malignant tumour of colon |
Ca colon NOS |
Malignant tumour of colon |
Ca esophagus NOS |
Malignant tumour of oesophagus |
Ca larynx - NOS |
Malignant tumour of larynx |
Ca larynx - NOS |
Malignant tumour of larynx |
Ca lip, oral, pharynx NOS |
Malignant neoplasm of lip, oral cavity and pharynx |
Ca lip, oral, pharynx NOS |
Malignant neoplasm of lip, oral cavity and pharynx |
Ca liver/biliary system NOS |
Carcinoma liver and/or biliary system (disorder) |
Ca liver/biliary system NOS |
Carcinoma liver and/or biliary system (disorder) |
Ca oesophagus NOS |
Malignant tumour of oesophagus |
Ca pancreas NOS |
Malignant tumor of pancreas |
Ca pancreas NOS |
Malignant tumor of pancreas |
Ca rectum + Ca anus NOS |
Malignant neoplasm of anorectum (disorder) |
Ca rectum + Ca anus NOS |
Malignant neoplasm of anorectum (disorder) |
Ca skin - other NOS |
Malignant neoplasm of skin (disorder) |
Ca skin - other NOS |
Malignant neoplasm of skin (disorder) |
Ca stomach NOS |
Malignant tumor of stomach |
Ca stomach NOS |
Malignant tumor of stomach |
Ca uterus NOS: [carcinoma] or [cancer] |
Malignant neoplasm of uterus (disorder) |
Ca uterus NOS: [carcinoma] or [cancer] |
Malignant neoplasm of uterus (disorder) |
Cabbage - dietary |
Cabbage (substance) |
Cabergoline [parkinsons] |
Product containing cabergoline (medicinal product) |
Caesarean delivery - delivered |
Deliveries by caesarean |
Caffeine and sodium benzoate injection |
Product containing caffeine and sodium benzoate (medicinal product) |
Caffeine containing substance - non-pharmaceutical |
Caffeine |
Café-au-lait spots and ring chromosome 11 |
Ring chromosome 11 syndrome |
Calcaneum X-ray |
Plain X-ray of calcaneum |
Calcaneum X-ray |
Plain X-ray of calcaneum |
Calcipotriene 0.005%/betamethasone 0.064% topical suspension |
Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 milliliter and calcipotriol 50 microgram/1 milliliter conventional release cutaneous lotion (clinical drug) |
Calcitonin, salmon 100unit/mL injection solution 1mL vial |
Product containing precisely salmon calcitonin 100 unit/1 milliliter conventional release solution for injection (clinical drug) |
Calcitonin, salmon 200iu/mL spray |
Product containing precisely salmon calcitonin 200 unit/1 actuation conventional release nasal spray (clinical drug) |
Calcitonin, salmon 200unt/mL injection |
Salmon calcitonin 200 unit/mL solution for injection |
Calcitonin, salmon 200unt/mL injection solution 2mL vial |
Salmon calcitonin 200 unit/mL solution for injection |
Calcium analyte |
Calcium |
Calcium antacid |
Calcium compound |
Calcium carbonate+cholecalciferol 1.25g/11micrograms/sachet granules |
Calcium carbonate 6.25 mg/mL and colecalciferol 2.2 unit/mL oral solution |
Calcium chloride 10% injection solution 10mL prefilled syringe |
Product containing precisely calcium chloride 100 milligram/1 milliliter conventional release solution for injection (clinical drug) |
Calcium hydroxyapatite microsphere suspension in aqueous based carrier 0.3mL prefilled syringe |
Hydroxyapatite only product in parenteral dose form |
Calcium hydroxyapatite microsphere suspension in aqueous based carrier 1.3mL prefilled syringe |
Hydroxyapatite only product in parenteral dose form |
Calcium phosphate+colecalciferol 3100mg/20micrograms/sachet powder for oral suspension |
Calcium phosphate and colecalciferol only product |
Calculus - composition |
Calculus chemical composition - finding |
Calculus exam. general |
Calculus examination |
Calculus examination NOS |
Calculus examination |
Calculus examination NOS |
Calculus examination |
Calculus examination general |
Calculus examination |
Calculus gen. exam. NOS |
Calculus examination |
Calculus general examination NOS |
Calculus examination |
Calculus of bile duct with acute cholecystitis without obstruction |
Bile duct calculus with acute cholecystitis |
Calculus of bile duct with chronic cholecystitis without obstruction |
Calculus of bile duct with chronic cholecystitis |
Calculus of bile duct without obstruction |
Calculus of bile duct |
Calculus of common bile duct with acute cholecystitis without obstruction |
Calculus of common bile duct with acute cholecystitis |
Calculus of common bile duct with chronic cholecystitis without obstruction |
Calculus of common bile duct with chronic cholecystitis (disorder) |